Skip to main content

Table 1 Patient demographic data

From: Clinical advantages of a newly launched anti-thrombotic PMMA membrane for the nutritional status and dialysis-related symptoms in older chronic dialysis patients: a multicenter pilot study

Items

All

NF group

n

Control group

n

p

 Number of patient

54

28

28

26

26

 

 Sex (male/female)

36/18

17/11

28

19/7

26

n.s.a

 Age (years)

76.4 ± 5.0 (70.0–87.0)

77.1 ± 4.8 (70.0–87.0)

28

75.6 ± 5.0 (70.0–87.0)

26

n.s.b

 Dialysis vintage (years)

8.3 ± 6.2 (0.5–30.0)

9.8 ± 7.4 (0.5–30.0)

28

6.8 ± 4.2 (1.0–15.0)

26

n.s.c

 Dry weight (kg)

52.5 ± 9.8 (33.8–90.0)

50.8 ± 8.8 (33.8–67.8)

28

54.3 ± 10.6 (34.5–90.0)

26

n.s. b

 Albumin concentration before dialysis (g/dL)

3.6 ± 0.3 (3.0–4.4)

3.6 ± 0.3 (3.1–4.0)

27

3.6 ± 0.3 (3.0–4.4)

25

n.s. b

Dialysis condition

 Blood flow rate (mL/min)

219.3 ± 30.3 (150–300)

218.9 ± 32.7 (150–300)

28

219.6 ± 28.2 (150–250)

26

n.s. b

 Dialysis time (h)

4.0 ± 0.4 (3.0–5.0)

4.0 ± 0.4 (3.0–5.0)

28

4.0 ± 0.3 (3.0–5.0)

26

n.s. b

 Effective surface area (m2)

1.7 ± 0.3 (1.3–2.1)

1.7 ± 0.3 (1.3–2.1)

28

1.7 ± 0.3 (1.4–2.1)

26

n.s. b

 Dialysis membrane (PS/PES/PEPA)

(32/12/10)

(13/8/7)

28

(19/4/3)

26

n.s. a

 Classification of dialyzer# (I·II/III/IV/V)

(0/6/26/22)

(0/1/16/11)

28

(0/5/10/11)

26

n.s. a

 Dialysate (with acetate/without acetate)

(44/10)

(20/8)

28

(24/2)

26

p < 0.05 a

Medical history

 Diabetes mellitus (Y/N)

(18/36)

(9/19)

28

(9/17)

26

n.s. a

 Cerebrocardiovascular event (Y/N)

(12/42)

(7/21)

28

(5/21)

26

n.s. a

  1. Results are presented as the mean ± standard deviation, and the values in parentheses represent the minimum and maximum values
  2. #Classification of dialyzers in the Japanese reimbursement system
  3. aChi-square test
  4. bUnpaired t test
  5. cWelch’s test